1.1 The Dynamic Spectral Imaging System (DYSIS) colposcope with DYSISmap shows promise and is recommended for assessing suspected cervical abnormalities in people having colposcopy. Centres using the technology should audit their outcomes (see section 5.16).
1.2 Further research is recommended on the effects of using the DYSIS colposcope with DYSISmap on clinical and patient outcomes in a human papilloma virus primary screening setting, and on patient experience (see sections 6.1 to 6.3).
1.3 The ZedScan I shows promise in assessing suspected cervical abnormalities, but there is currently not enough evidence to recommend its routine adoption. Further research on the effects of using the technology on clinical and patient outcomes is recommended (see sections 6.1 to 6.3). Colposcopy services that implemented the ZedScan I before this guidance was published are encouraged to take part in studies that address these research recommendations.